Impact of the COVID-19 pandemic on nuclear medicine departments in Europe

The effect of COVID-19 on nuclear medicine and radiopharmacy activities: A global survey

Globally, COVID-19 affected radiopharmaceutical laboratories. This study sought to determine the economic, service, and research impacts of COVID-19 on radiopharmacy. This online survey was conducted with the participation of employees from nuclear medicine and radiopharmaceutical companies. The socioeconomic status of the individuals was collected. The study was participated by 145 medical professionals from 25 different countries. From this work, it is evident that 2-deoxy-2-[18F]fluoro-D-glucose (2-[18F]FDG), and 99mTc-labeled macro aggregated albumin 99mTc-MAA were necessary radiopharmaceuticals used by 57% (83/145and 34% (49/145;) respondents, respectively for determining how COVID infections affect a patient's body. The normal scheduling procedure for the radiopharmacy laboratory was reduced by more than half (65%; 94/145). In COVID-19, 70% (102/145) of respondents followed the regulations established by the local departments. Throughout the pandemic, there was a 97% (141/145) decrease in all staffing recruitment efforts. The field of nuclear medicine research, as well as the radiopharmaceutical industry, were both adversely affected by COVID-19.

Future development of global molybdenum-99 production and saving of atmospheric radioxenon emissions by using nuclear fusion-based approaches

Technetium-99m, the decay product of molybdenum-99, is the most used medical isotope in diagnostic imaging. The future disruptions of molybdenum-99 supply, due to the final shut down of some old producing reactors, has led some current global supplies to plan the expansion of their production capacity. While other countries are developing own production facilities to supply their domestic demand. The global increase of molybdenum-99 production in the coming years could increase by about five times the current demand, with about the 50 percent of additional production in North America. Xenon radionuclides are an inevitable by-product of the nuclear plants production, and their periodically release into the atmosphere, contribute to the background that is also revealed by the IMS stations of the CBTO treaty. In this framework, the development of new technologies, posing no risk in relation to nuclear proliferation and do not result in emissions of radioxenon, could mitigate the issues related to the forecast increase of molybdenum-99 production worldwide. In Italy, an alternative 99Mo production project, the project ENEA Sorgentina, based on the irradiation of molybdenum by neutrons produced by a deuterium-tritium nuclear fusion process, is under development. This facility will not release radioxenon into the atmosphere, so it will not affect the background value in the atmosphere in Southern Europe.

Oncology and cardiology positron emission tomography/computed tomography faced with COVID-19: A review of available literature data

The COVID-19 pandemic has forced people to significantly change their lifestyles and attitudes, and has greatly burdened healthcare delivery systems worldwide. The redistribution of the medical delivery system to maintain normal medical care while responding generously to COVID-19 is a continuing challenge that weighs heavily on medical institutions. Among imaging modalities, chest X-rays and computed tomography (CT) examinations have clearly made a large contribution to treatment of COVID-19. In contrast, it is difficult to express the standpoint of nuclear medicine examinations in a straightforward manner, as the greatest emphasis in this modality has been on how necessary medical care can continue to be provided. Many clinical reports of nuclear medicine examinations related to COVID-19 have been published, and knowledge continues to accumulate. This review provides a summary of the current state of oncology and cardiology positron emission tomography (PET) examinations related to COVID-19, and includes preparation of the nuclear medicine department, trends in PET examinations, specific imaging findings on 18F-fluorodeoxyglucose (FDG) PET/CT, imaging of complications of COVID-19, PET tracers other than FDG, and the effects of vaccines on PET imaging findings.